Update regarding Company''s intimated dated May 10, 2025 in relation to movement in Senior Management Personnel.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma is providing an update to its May 10, 2025 intimation about changes in its Senior Management Personnel (SMP). Two executives — Ms. Sangeetha K (Head of Regulatory Affairs) and Ms. Bharathi R (Head of Global Procurement) — ceased to be part of Strides' SMP because they took on advisory roles in group companies, effective March 31 and April 30, 2025 respectively. Two new officials — Mr. K N Swamy (Head of Global Analytical – Development & Services) and Mr. Sugeet Chopra (Head of Procurement and Supply Chain) — were identified as SMP effective May 1, 2025. The company also disclosed that BSE had to send a reminder on July 18, 2025 about a delay in making the original announcement, which Strides attributed to administrative reasons and expressed regret for.
The actual SMP changes appear routine — personnel moving into group-level advisory roles and internal promotions filling the slots — so direct operational impact is limited. However, the fact that BSE had to flag a delayed disclosure raises a mild governance red flag and could dent investor confidence in the company's compliance processes, though no penalties have been mentioned.